香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 認購結構性存款產品 須予披露的交易 認購平安銀行結構性存款產品 近日，本公司與平安銀行訂立平安銀行結構性存款產品協議 I，同意以日常營運產生的自有閑置 資金向平安銀行認購總金額為人民幣 3.00 億元的結構性存款產品；並與平安銀行訂立平安銀行結 構性存款產品協議 II，同意以 A 股公開發行所得暫時閑置募集資金向平安銀行認購總金額為人民 幣 0.57 億元的結構性存款產品。 上市規則的涵義 根據上市規則第 14.22 條，平安銀行結構性存款產品協議項下的交易需合併計算。在訂立平安銀 行結構性存款產品協議時，就平安銀行結構性存款產品協議項下產品的總認購金額合計而言，一 項或多項適用百分比率（定義見上市規則第 14.07 條）超過 5%但均低於 25%，故根據上市規則第 14章，该等交易構成本公司之須予披露的交易，須遵守上市規則第14章有關申報及公告之規定， 惟獲豁免遵守獨立股東批准之規定。 概述 近日，本公司 ...

Financial Performance - The proposed cash dividend for 2023 is RMB 0.7 per share, totaling RMB 72,560,047, which accounts for 66.80% of the net profit attributable to shareholders [6]. - The company's operating revenue for 2023 was ¥850,733,212, a decrease of 17.50% compared to ¥1,031,159,838 in 2022 [23]. - The net profit attributable to shareholders for 2023 was ¥108,627,368, down 21.28% from ¥137,997,098 in 2022 [23]. - The basic earnings per share for 2023 was ¥0.11, a decline of 15.38% from ¥0.13 in 2022 [23]. - The net profit after deducting non-recurring gains and losses for 2023 was ¥69,893,731, a decrease of 37.62% from ¥112,051,414 in 2022 [23]. - The weighted average return on equity for 2023 was 4.69%, down 1.52 percentage points from 6.21% in 2022 [23]. - The company's total assets at the end of 2023 were ¥2,876,687,507, a decrease of 3.34% from ¥2,976,007,272 at the end of 2022 [23]. - The net cash flow from operating activities for 2023 was ¥71,015,450, a significant decrease of 57.03% compared to ¥165,268,622 in 2022 [23]. - The company's total revenue for 2023 was 851 million RMB, representing a year-on-year decrease of 17.50% [31]. - The company's total operating revenue for 2023 was approximately RMB 850,733,212, a decrease of 17.50% from RMB 1,031,159,838 in 2022 [111]. Research and Development - Research and development expenses accounted for 28.76% of operating revenue, an increase of 6.10 percentage points from 22.66% in 2022 [23]. - The company achieved a total R&D investment of CNY 244,700,356 in the reporting period, representing a 4.73% increase from the previous year [77]. - The proportion of R&D investment to operating income increased by 6.10 percentage points to 28.76% [77]. - The company filed for 25 new patents during the reporting period, with 18 patents granted, bringing the total granted patents to 119 [76]. - The company is focusing on innovative drug development using gene engineering, photodynamic technology, and nanotechnology, targeting skin diseases, tumors, and Parkinson's disease [32]. - The company has established a gene engineering technology platform, focusing on the development of cytokine, fusion protein, monoclonal antibody, and antibody-drug conjugate products, with plans to enhance clinical research and registration for gene drugs [68]. - The company is advancing several new drug candidates, including FZJ-003 for atopic dermatitis and ulcerative colitis, both of which are in Phase II clinical trials and at the international advanced level [90]. - The company is actively pursuing clinical trials for various drugs, including those for advanced solid tumors and HPV-related diseases [81]. - The company has a strong pipeline with multiple projects in various stages of clinical trials, including Hemoporfin, which is at the international leading level in Phase IV clinical research [89]. Market and Industry Trends - The global pharmaceutical market is expected to grow at a compound annual growth rate (CAGR) of 3-6% from 2023 to 2027, reaching approximately $1.9 trillion [56]. - China's pharmaceutical market achieved a CAGR of 3.70% from 2016 to 2020, with a total market size of $221.4 billion in 2020, projected to reach $349.8 billion by 2025 and $457.4 billion by 2030 [57]. - The biopharmaceutical industry in China is experiencing significant growth opportunities, supported by national policies and increasing health awareness among residents [48]. - The global oncology spending is projected to reach $370 billion by 2027, driven by the introduction of new drugs and biosimilars [53]. - The company is positioned to benefit from the increasing healthcare demands driven by an aging population and rising income levels in China [62][63]. Corporate Governance and Management - The board of directors and management have confirmed the accuracy and completeness of the annual report [5]. - The company has established a robust management framework to enhance transparency and accountability, ensuring scientific decision-making and protecting shareholder interests [45]. - The company strictly adhered to information disclosure regulations, ensuring timely and accurate information dissemination to all stakeholders [194]. - The company implemented a management system for insider information, minimizing the number of individuals with access to sensitive information [195]. - The management team has been rejuvenated with new appointments, enhancing the company's innovation capabilities and strategic development [95]. Sales and Marketing Strategies - The company aims to adapt its sales strategies to market changes to enhance competitiveness and ensure continuous revenue contribution from its products [31]. - The company employs a distribution model for product sales, with its photodynamic therapy drugs marketed by its own team and Ribao Duo® marketed by a professional CSO team [44]. - The company is focusing on the domestic academic promotion of its listed products and plans to expedite international registration for greater market reach [105]. - The company emphasizes academic promotion as a key marketing strategy, utilizing diverse online platforms for clinical exchanges and case sharing among dermatologists [93]. - The company is actively exploring new sales models to address common challenges in the current marketing environment and improve patient access to treatments [93]. Risks and Challenges - The company faces risks related to the loss of core technical personnel, which could impact its competitive advantage and profitability [98]. - The company is exposed to drug price reduction risks due to government policies and market competition [101]. - The pharmaceutical industry faces challenges such as rising costs and intensified competition due to regulatory changes and market dynamics [56]. - The company has not ventured into new industries, new business formats, or new models during the reporting period [65]. Product Development and Innovations - The company is a leader in photodynamic therapy, holding the largest product line and sales in the global market for photodynamic drugs [59]. - The company successfully launched the first domestic formulation of Doxil (liposomal doxorubicin) in 2009, which is now recommended for first-line treatment of various cancers [60]. - The company is expanding research on photodynamic drugs for multiple indications, including cervical precancerous lesions and acne, while also exploring international registration for its marketed drugs [71]. - The company aims to achieve new indication registrations for ALA in treating cervical precancerous lesions and other skin diseases [150]. - The company is focused on developing new sensitizers and medical devices to support its photodynamic treatment and diagnosis technologies [149]. Financial Management - The company has not reported any non-operating fund occupation by controlling shareholders or related parties [8]. - The company has not violated decision-making procedures for external guarantees [8]. - The company has not achieved profitability since its listing [5]. - The company has a balanced approach to drug development, focusing on both innovative and generic products to meet clinical needs [87]. - The company’s capitalized R&D investment decreased by 86.23% to CNY 937,381, indicating a conservative approach to capitalizing R&D projects [77].

Financial Performance - The company's revenue for the year ended December 31, 2023, was RMB 850,733,000, a decrease of 17.5% compared to RMB 1,031,160,000 in 2022[2] - Profit before tax for the same period was RMB 97,528,000, down 26.3% from RMB 132,294,000 in the previous year[2] - The net profit attributable to shareholders for 2023 was RMB 108,627,000, a decline of 21.3% from RMB 137,997,000 in 2022[2] - The company reported a total comprehensive income of RMB 107,793,000 for 2023, compared to RMB 136,122,000 in 2022, indicating a decline of 20.8%[2] - The total operating profit for 2023 was RMB 45,580,116, down from RMB 105,919,554 in 2022[13] - The company reported a net financial loss of ¥3,703,638 in 2023, compared to a loss of ¥8,788,607 in 2022, showing an improvement[188] - The total profit for 2023 was RMB 97,528,063, a decrease of 26.3% compared to RMB 132,293,548 in 2022[197] Assets and Liabilities - Total assets as of December 31, 2023, amounted to RMB 2,876,688,000, a decrease from RMB 2,976,007,000 in 2022[3] - Total liabilities decreased to RMB 518,124,000 in 2023 from RMB 722,986,000 in 2022, representing a reduction of 28.3%[3] - Cash and cash equivalents as of December 31, 2023, were RMB 1,195,895,997, down from RMB 1,289,302,664 in 2022[4] - The company's total equity attributable to shareholders increased to RMB 2,357,554,000 in 2023 from RMB 2,257,102,000 in 2022, marking an increase of 4.4%[3] - The company's total equity as of December 31, 2023, was RMB 2,358,563,368, an increase from RMB 2,253,021,355 at the end of 2022[18] - The company's total equity as of December 31, 2023, was RMB 2,379,229,295, an increase from RMB 2,321,921,130 at the end of 2022[20] Earnings Per Share - The company's basic and diluted earnings per share for 2023 were RMB 0.1051, down from RMB 0.1340 in 2022, reflecting a decrease of 21.5%[2] - Basic earnings per share for 2023 were RMB 0.11, down from RMB 0.13 in 2022, a decrease of 15.4%[12] - Diluted earnings per share remained at RMB 0.11 for 2023, unchanged from 2022 despite adjustments for potential ordinary shares[200] Cash Flow - Cash flow from operating activities for 2023 was RMB 71,015,450, down from RMB 165,268,622 in 2022[14] - The net cash flow from operating activities in 2023 was RMB 10,422,159, down from RMB 122,058,916 in 2022, indicating a significant decline[15] - The total cash inflow from investment activities in 2023 was RMB 3,835,875,490, an increase of 10.5% from RMB 3,469,785,915 in 2022[15] - The cash outflow for investment activities in 2023 was RMB 3,848,247,323, compared to RMB 3,500,564,593 in 2022, reflecting a rise of 9.9%[15] - The company's cash balance at the end of 2023 was RMB 1,067,294,432, down from RMB 1,187,769,137 at the end of 2022[15] Research and Development - Research and development expenses increased to RMB 243,762,975 in 2023, compared to RMB 226,850,903 in 2022, reflecting a growth of 7.4%[10] - The total research and development expenses for 2023 were RMB 244,700,356, an increase from RMB 233,659,131 in 2022[145][146] - R&D expenses for 2023 totaled ¥94,014,517, slightly down from ¥95,009,511 in 2022, while salary expenses in R&D increased to ¥75,383,005 from ¥57,590,255[187] Inventory and Receivables - The inventory increased to RMB 29,993,697 in 2023 from RMB 19,268,923 in 2022, an increase of 55.5%[9] - The provision for bad debts increased to RMB 35,993,681 as of December 31, 2023, compared to RMB 12,365,732 on December 31, 2022, reflecting a significant rise in credit loss provisions[98][102] - The aging analysis of accounts receivable shows that the amount overdue within one year was RMB 476,025,167, down from RMB 516,855,117 in the previous year, indicating improved collection efficiency[99] - The total amount of accounts receivable written off during the year was RMB 271,600, with a corresponding bad debt provision of the same amount[106] Government Grants and Taxation - The company received government subsidies related to income amounting to ¥20,638,461 in 2023, compared to ¥7,868,017 in 2022, indicating a substantial increase[191] - The corporate income tax rate applicable to the company for 2023 remains at 15%, consistent with 2022[90] - The company has received the "High-tech Enterprise Certificate" valid for three years, allowing it to maintain the reduced corporate income tax rate of 15%[89] Accounting Policies and Compliance - The company has updated its accounting policies in accordance with the Ministry of Finance's guidelines, which did not have a significant impact on the financial statements[3] - The financial statements were approved by the board of directors on March 28, 2024, indicating a commitment to transparency and compliance[23] - The company’s accounting policies are aligned with the Chinese Accounting Standards and reflect its operational characteristics[24] Shareholder Information - The company distributed dividends totaling RMB 72,560,047 to shareholders in 2023[18] - The company declared a cash dividend of RMB 0.07 per share for the 2022 fiscal year, totaling RMB 72,560,047 based on 1,036,572,100 shares issued[179]

上海复旦张江生物医药股份有限公司 2023 年度独立董事述职报告 作为上海复旦张江生物医药股份有限公司（以下简称"公司""本公司"）董事 会独立非执行董事（亦称"独立董事"），本人严格按照《中华人民共和国公司法》 （以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、 《上海证券交易所科创板股票上市规则》《香港联合交易所有限公司证券上市规 则》等法律、法规、规范性文件及《公司章程》的要求，于 2023 年度任职期间， 积极参加公司董事会及各专门委员会会议，认真审议各项议案，切实履行了独立 董事的职责和义务，审慎行使了公司和股东所赋予的权利，维护了全体股东的合 法利益，充分发挥独立董事的作用。现将本人 2023 年度履职情况报告如下： 一、 独立董事的基本情况 2023 年 5 月 30 日，公司完成了董事会换届选举工作。公司 2022 年度股东 周年大会选举本人担任公司第八届董事会独立董事，任期三年。 （一）本人的工作履历、专业背景及兼职情况如下： 徐培龙，1977 年出生，于二零二三年五月三十日获委任为公司独立非执行 董事。本人系国家一级律师，现任上海市君悦律师事务所党总支书记、高级合伙 ...

股票代码：688505 股票简称：复旦张江 编号：临 2024-004 上海复旦张江生物医药股份有限公司 关于 2023 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每 10 股派发现金红利人民币 0.7 元（含税）。公司本年度不进行转增，不 送红股； 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确； 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股派 发现金红利金额不变，相应调整分配的总额，并将另行公告具体调整情况。 一、2023年度利润分配方案内容 经普华永道中天会计师事务所（特殊普通合伙）审计，上海复旦张江生物医 药股份有限公司（以下简称"公司"）2023年度归属于上市公司股东的净利润为人 民币108,627,368元。截至2023年12月31日，母公司累计可供分配利润为人民币 850,670,452元。经董事会决议，公司2023年度拟以实施权益分派股权登记日登记 的总股本为基数分配利润。本次利润分配方案如下： 公司 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海复旦张江生物医药股份有限公司（以下简称"公司""本公司"或"复旦张 江"）于 2024 年 3 月 28 日召开了第八届董事会第五次会议及第八届监事会第四 次会议，审议通过了《关于作废 2021 年限制性股票激励计划部分已授予尚未归 属的限制性股票的议案》，现将有关事项说明如下： 一、本次限制性股票激励计划已履行的决策程序和信息披露情况 股票代码：688505 股票简称：复旦张江 编号：临 2024-009 上海复旦张江生物医药股份有限公司关于 作废 2021 年限制性股票激励计划部分已授予尚未归属的 限制性股票的公告 （一）2021 年 4 月 6 日，公司召开第七届董事会第七次（临时）会议及第 七届监事会第七次（临时）会议，审议通过了《关于<公司 2021 年限制性股票激 励计划（草案）>及其摘要的议案》等相关议案。公司独立董事对该事项发表了 同意的独立意见。公司监事会对公司 2021 年限制性股票激励计划的相关事项进 行核实并出具了相关核查意见。2021 年 4 月 ...

（2024 年 3 月 28 日由董事会通过） 上海复旦张江生物医药股份有限公司 董事会提名委员会议事规则 提名委员会议事规则 第一章 提名委员会的组成 第一条 上海复旦张江生物医药股份有限公司（以下称"公司"）根据《中华人民 共和国公司法》、《上海复旦张江生物医药股份有限公司章程》（以下称"《公司章 程》"）、《上海复旦张江生物医药股份有限公司董事会议事规则》、《上海证券交易所 科创板股票上市规则》和《香港联合交易所有限公司证券上市规则》的相关规定，设 立董事会提名委员会，并制定本规则。本规则应同时遵守《上海证券交易所科创板股 票上市规则》和《香港联合交易所有限公司证券上市规则》（以下合称"《上市规则》"） 的相关规定，如两个上市规则规定不一致时，按从严原则执行。 第二条 提名委员会是董事会下设专门委员会。 第三条 提名委员会由三名董事组成，独立非执行董事人数应过半数。 第四条 提名委员会委员由董事会主席或三分之一以上董事或二分之一以上的 独立非执行董事提名，经董事会选举。 第五条 提名委员会设主席（即召集人，下同）一名，由独立非执行董事担任并 由公司董事会主席提名，并经董事会任命，领导提名委员会并主持提名 ...

股票代码：688505 股票简称：复旦张江 编号：临 2024-012 上海复旦张江生物医药股份有限公司 关于副总经理离职暨核心技术人员调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海复旦张江生物医药股份有限公司（以下简称"公司"或"复旦张江"）董 事会近日收到公司副总经理暨核心技术人员李晓闻女士的书面辞职报告。李晓闻 女士因个人原因申请辞去所任职务，辞任后，李晓闻女士将不再担任公司任何职 务，辞职报告自送达公司董事会之日起生效。李晓闻女士负责的工作正在进行交 接，其离职不会对公司的研发能力、持续经营能力和核心竞争力产生重大不利影 响，不会影响公司现有核心技术及研发项目的工作开展，公司的研究开发及临床 运营管理工作均有序推进。 公司核心技术人员陶纪宁女士因工作岗位调整将不再直接参与公司核心 研发工作，仍在公司担任其他职务，其负责的工作已完成交接。基于陶纪宁女士 工作职责发生变化，公司不再认定其为核心技术人员。 公司结合刘柯桢先生、张一帆先生的任职履历，以及对公司核心技术研 发的参与情况与业务 ...

股票代码：688505 股票简称：复旦张江 编号：临 2024-011 上海复旦张江生物医药股份有限公司 关于计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海复旦张江生物医药股份有限公司（以下简称"公司"）于2024年3月28日 召开第八届董事会第五次会议、第八届监事会第四次会议，审议通过了《关于计 提资产减值准备的议案》，现将相关情况公告如下： 一、计提资产减值准备的情况概述 根据《企业会计准则》和公司会计政策的相关规定，为客观、公允地反映公 司2023年12月31日的财务状况和2023年度的经营成果，公司及下属子公司（以下 简称"本集团"）对截至2023年12月31日的公司资产进行了充分的评估和分析，本 着谨慎性原则，并与公司审计师进行了充分的沟通，对相关资产进行了减值测试 并计提了相应的资产减值准备。2023年度公司计提各类资产减值准备共计 32,643,827元，具体如下： 单位：人民币元 | 项 | 目 | 2023年度计提金额 | | --- | --- | --- | | 信用减值 ...

上海复旦张江生物医药股份有限公司 2023 年度财务报表及审计报告 . 上海复旦张江生物医药股份有限公司 2023 年度财务报表及审计报告 | | 页码 | | --- | --- | | 审计报告 | 1 - 7 | | 2023 年度财务报表 | | | 合并及公司资产负债表 | 8 - 11 | | 合并及公司利润表 | 12 - 14 | | 合并及公司现金流量表 | 15 - 16 | | 合并及公司股东权益变动表 | 17 - 19 | | 财务报表附注 | 20 - 119 | | 补充资料 | 1 - 3 | 普华永道 审计报告 普华永道中天审字(2024)第 10115 号 (第一页,共七页) 上海复旦张江生物医药股份有限公司全体股东: í 审计意见 (一) 我们审计的内容 我们审计了上海复旦张江生物医药股份有限公司(以下简称"贵公司")的 财务报表,包括 2023年 12月 31日的合并及公司资产负债表,2023 年度的 合并及公司利润表、合并及公司现金流量表、合并及公司股东权益变动表以 及财务报表附注。 (二) 我们的意见 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编 ...